Finding a Needle in a Haystack: Design and Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify Asymptomatic SARS-CoV-2 Infection

Authors: Apurv Soni MD PhD[1,2,3], Carly Herbert BA[1], Caitlin Pretz MS[1], Pamela Stamegna MD[1], Andreas Filippaios MD[1], Qiming Shi MS[1, 3, 4], Thejas Suvarna BBA BS[5], Emma Harman MPH[5], Summer Schrader BA[5], Chris Nowak BA[5], Eric Schramm PharmD[5], Vik Kheterpal MD[5], Stephanie Behar BA[1], Seanan Tarrant BA[1], Julia Ferranto BS[1], Nathaniel Hafer PhD[4], Matthew Robinson MD[6], Chad Achenbach MD[7], Robert L. Murphy MD[7], Yukari C. Manabe MD[6], Laura Gibson MD[8], Bruce Barton PhD[2], Laurel O'Connor MD[9], Nisha Fahey DO ScM[10], Elizabeth Orvek MS[2], Peter Lazar BS[2], Didem Ayturk MS[2], Steven Wong BS[2], Adrian Zai MD PhD MPH[2], Lisa Cashman MPH[11], Lokinendi V Rao PhD[11], Katherine Luzuriaga MD[4], Stephenie Lemon PhD[2], Allison Blodgett PhD[4], Elizabeth Trippe PhD[12], Mary Barcus MD[12], Brittany Goldberg MD[12], Kristian Roth PhD[12], Timothy Stenzel MD PhD[13], William Heetderks PhD[14], John Broach MD MPH MBA[9], David McManus MD ScM[1,3,15]

AS and CH contributed equally to this work

Affiliations:

[1]Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA

[2]Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, USA

[3]Division of Health System Science, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA

[4]University of Massachusetts Center for Clinical and Translational Science, University of Massachusetts Chan Medical School, Worcester, MA, USA

[5]CareEvolution, LLC, Ann Arbor, MI, USA

[6]Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[7]Division of Infectious Disease, Department of Medicine, Havey Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

[8]Division of Infectious Disease, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA

[9]Department of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA

[10]Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA, USA

[11]Quest Diagnostics, Marlborough, MA, USA

[12]Division of Microbiology, OHT7 Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland

13OHT7 Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, Maryland

14National Institute of Biomedical Imaging and Bioengineering, NIH, via contract with Kelly Services, Bethesda, MD, USA

15Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA

Corresponding Author:

Apurv Soni, M.D., Ph.D.

Program in Digital Medicine, Department of Medicine

S6-757, Medical School Building

55 Lake Avenue N

Worcester, MA, 01605

Apurv.soni@umassmed.edu

Abstract:

Background: Rapid antigen tests (Ag-RDT) for SARS-CoV-2 with Emergency Use Authorization

generally include a condition of authorization to evaluate the test's performance in

asymptomatic individuals when used serially.

Objective: To describe a novel study design to generate regulatory-quality data to evaluate

serial use of Ag-RDT in detecting SARS-CoV-2 virus among asymptomatic individuals.

Design: Prospective cohort study using a decentralized approach. Participants were asked to

test using Ag-RDT and molecular comparators every 48 hours for 15 days.

Setting: Participants throughout the mainland United States were enrolled through a digital

platform between October 18, 2021 and February 15, 2022. Ag-RDTs were completed at home,

and molecular comparators were shipped to a central laboratory.

Participants: Individuals over 2 years old from across the U.S. with no reported COVID-19

symptoms in the 14 days prior to study enrollment were eligible to enroll in this study.

Measurements: Enrollment demographics, geographic distribution, and SARS-CoV-2 infection

rates are reported.

Key Results: A total of 7,361 participants enrolled in the study, and 492 participants tested

positive for SARS-CoV-2, including 154 who were asymptomatic and tested negative to start the

study. This exceeded the initial enrollment goals of 60 positive participants. We enrolled

participants from 44 U.S. states, and geographic distribution of participants shifted in

accordance with the changing COVID-19 prevalence nationwide.

Limitations: New, complex workflows required significant operational and data team support.

Conclusions: The digital site-less approach employed in the 'Test Us At Home' study enabled

rapid, efficient, and rigorous evaluation of rapid diagnostics for COVID-19, and can be adapted

across research disciplines to optimize study enrollment and accessibility.

INTRODUCTION

Over-the-counter rapid antigen SARS-CoV-2 tests (Ag-RDT) present unique
opportunities for widespread COVID-19 testing. However, the authorization of these tests under
the Food and Drug Administration's (FDA) Emergency Use Authorization (EUA) generally
imposes a requirement on companies to evaluate their test's performance for detecting
asymptomatic infections with serial screening. To satisfy this requirement, it was necessary to
conduct a longitudinal study to observe the onset of SARS-CoV-2 infection and performance of
Ag-RDT across the course of infection.[5] This required an innovative research design to generate
regulatory-quality, representative data, capture new-onset infections amidst a changing
pandemic, and understand asymptomatic infections, which represent a small proportion of all
SARS-CoV-2 cases.

This manuscript describes the design, implementation, and completion of a novel, digital,
site-less study called 'Test Us at Home' funded by the National Institutes of Health (NIH) Rapid
Acceleration Diagnostics (RADx) Program. In this manuscript, we outline the rationale for key
decision-making and describe findings of the operational effort needed to successfully collect
data under this paradigm, to provide rapid, rigorous evaluation of over-the-counter diagnostics
across diverse participants of all ages in community-based settings.

METHODS
Study Design:
This prospective cohort study recruited participants over two-years old who were asymptomatic
and self-reported absence of SARS-CoV-2 infection in the three months prior to enrollment.
Participants were asked to test for SARS-CoV-2 via Ag-RDT and molecular comparator every
48-hours for 15 days. This study was approved by the Institutional Review Board of the WIRB-
Copernicus Group.
Study Objectives:

The primary objective of this collaboration between the FDA, NIH, and the RADx Tech Clinical

Studies Core at UMass Chan Medical School was to generate right-of-reference data that could

be used towards FDA EUA. To accomplish this, we aimed to evaluate the performance of serial

use of three different Ag-RDT to detect a new-onset SARS-CoV-2 infection, as determined by a

laboratory-based molecular test.

Study Population and Recruitment: To approximate the performance of Ag-RDT in the general

public, the FDA suggested against preferentially enrolling participants with a known SARS-CoV-

2 exposure (oral communication, August 3, 2021). The goal of the study was to recruit at least

60 participants who started the study without any symptoms and with a negative SARS-CoV-2

molecular test and subsequently tested positive during the study period. Due to the fluctuating

rates of COVID-19 positivity and the importance of recruiting asymptomatic participants, we

employed a decentralized study design whereby eligible participants from anywhere in the

mainland United States except for Arizona could participate. Residents from the state of Arizona

were excluded because Quest Diagnostics, the laboratory performing molecular tests, did not

provide direct-to-consumer tests in that state. Additional inclusion and exclusion criteria are

listed in Supplemental Table 1. Recruitment relied on the engagement of community

stakeholders to advertise the study and reach communities nationwide. Periodic analyses were

conducted to inform enrollment goals based on observed precision for positive percent

agreement.

Enrollment: Participants who expressed interest in the study received an email or flyer with

instructions for downloading the study app and performing eligibility screening. The study app

was a custom interface designed through the MyDataHelps platform. To enroll, participants

answered a series of questions to determine their eligibility and prioritization status. All eligible

participants underwent automated prioritization based on a-priori criteria that were adjusted on a

daily or weekly basis (Supplemental Figure 1, Supplemental Figure 2). We adjusted

prioritization criteria to preferentially enroll populations based on their region's SARS-CoV-2

transmission rates, community-level vaccination, and sociodemographic characteristics. This

step occurred prior to consenting, and data was discarded if the participant did not enroll in the

study before the data collection period ended; these data were never accessible to the study

team unless the participant consented to take part in the study. Eligible participants who did not

match the preferred criteria for enrollment received a note saying that they cannot enroll in the

study at this time but would receive communication from the study team when/if they became

eligible (Supplemental Figure 3). These participants were placed on a "waiting list", which was

reviewed with regard to changing priority criteria throughout the study.

If eligible for enrollment, participants 18 years of age or older were asked to read the e-

consent form and provide their signature through the study app (Supplemental Figure 4).

Participants younger than 18 years were asked to review the e-assent and e-consent form with

the support of their parent(s) or guardian(s) and provide assent for participation, while the

parent/guardian provided written consent for participation in the study. Participants were eligible

to receive up to $250 for timely completion of all sample collections (Supplemental Figure 5).

Test Distribution: On enrollment, participants were asked to provide their shipping information

through the study app. Participants were assigned to one of three Ag-RDT (Quidel QuickVue At-

Home OTC COVID-19 Test, Abbott BinaxNOW COVID-19 Antigen Self Test, or BD Veritor™ At-

Home COVID-19 Test) using an automated algorithm that was informed by the investigators'

discretion based on enrollment numbers and geographic location of the participants

(Supplemental Figure 6). The three Ag-RDT used in the study are authorized for emergency use

by the FDA and were selected to provide multiple assessments and facilitate generalizing

results to non-participating companies. These tests will be hereby referred to as test brands A,

B, and C (randomly assigned), as the purpose of the study was not to directly compare different

test performances. Participants residing together and enrolling with the same address or

enrolled in a group, such as a cohort of classmates, were assigned the same Ag-RDT, to avoid

mixing of test types between participants. Groups were given unique codes to input on

enrollment, to ensure members were easily identifiable. As a result of this strategy, the

assignment of tests to participants was non-random, and we intentionally did not pursue a

strategy to compare performance between different tests.

Because molecular assays require a prescription by a licensed physician, the study team

contracted with PWNHealth, a national clinician network, and developed an automated order

filing system with Quest Diagnostics to place the requisite orders (Supplemental Figure 7). A

total of 10 Ag-RDT and 7 home-collection kits for molecular comparators were provided to each

participant. Participants received Ag-RDT and PCR home-collection kits by mail through

separate shipments. The study team provided additional tests to participants if needed (e.g.

tests were damaged upon delivery or lost in the mail).

Testing Schedule: Participants were asked to perform the Ag-RDT and collect the specimen for

molecular comparator testing on the same day every 48 hours during the 15-day testing period

(Supplemental Figure 8). Immediately prior to testing, participants were asked to record any

symptoms on the day of testing. The study app provided a push-notification testing reminder at

the 44-hour mark and additional notifications every two hours until the 52-hour mark if the

participant had not completed their tests. Participants were instructed via the app to have at

least a 15-minute break between the Ag-RDT and the sample collection for molecular tests.

Participants were asked to record the results of the Ag-RDT when available by selecting one of

the following options: "Negative", "Positive", "Invalid", or "Don't Know", and upload a photo of the

test strip through the app (Supplemental Figure 9). Participants assigned to Test C were also

asked to download the Test C company-specific app which contained a test reader. The

company test reader asked participants to upload a photo of the test strip and provided Ag-RDT

results in real time. Test C users were asked to report the test result given by the test reader,

rather than self-interpretation, to the study app. If the participant tested positive by Ag-RDT, they

were told to contact their healthcare provider for any medical questions. In the event of an

invalid Ag-RDT result, the participant was asked to perform a second Ag-RDT. If the second Ag-

RDT result was also invalid, the participant was not asked to perform additional Ag-RDT on that

day and was instructed to continue to the PCR sample collection (at least 15 minutes after Ag-

RDT sample collection). Participants were responsible for shipping the PCR collection kit

containing the sample using the pre-paid FedEx envelope using instructions provided by Quest

Diagnostics, which were authorized by the FDA for emergency use.

Molecular Testing Procedures: Due to concerns of potential false-positive molecular tests, the

FDA recommended the use of two types of molecular assays, and potentially, a third assay, if

the prior two assays were discordant (oral communication, August 3, 2021).[23,4] Once participant

samples were received at Quest Diagnostics, the sample was divided into aliquots to perform

Roche Cobas 6800 SARS-CoV-2 PCR and Quest RC COVID-19 PCR DTC for all participants

(Supplemental Figure 10). An additional aliquot was preserved by the laboratory to allow for

testing on Hologic Aptima SARS-CoV-2 Transcription Mediated Amplification (TMA) assay if

Roche Cobas and Quest LDT were discordant or inconclusive. All three molecular assays used

were highly sensitive, authorized by EUA, and run per instructions per use. Remnant samples of

sample fluid from home-collection kits were frozen at -80 Celsius and shipped to UMass Chan

Medical School for future testing. Results of the molecular PCR assays were available to

participants through the Quest results portal and communication from the study team. All

participants that tested positive by molecular test received a phone call from a study team

member. In the event of discordant results, the participant was contacted by the study staff to

explain the results.

Communication with the study team: Participants were provided a study hotline staffed with

research coordinators to provide support during extended hours during the weekdays from 8 AM

to 9 PM EST. Participants were also able to contact the study team via email at all times. All

calls between coordinators and participants were documented in a call log containing the length

of the call, the reason for the call, narrative about the call, and whether the issue was resolved.

Data Management: There were three primary sources of data (Supplemental Figure 11). All

participant-reported data were collected through the study app and downloaded incrementally

through secure file transfer protocol to UMass Chan servers. The molecular testing data were

shared by Quest Diagnostics through an established datafeed between Quest and UMass Chan

servers. However, the PCR cycle threshold (CT) values and results of the tiebreaker assays

were not part of routinely abstracted data and required manual abstraction. Finally, tracking

reports were used to document all communications between participants and the study staff. All

three sources of data were combined using a participant's unique identifier assigned by the

study app. Paired Ag-RDT and PCR data were merged by matching on participant identifier and

date of testing. When test dates were not aligned or there were unmatched results, a member of

the study team reviewed all testing data from the participants to adjudicate paired findings. The

most common reason for mismatched dates was due to missing dates of collection or

transcription errors, as date of collection for PCR sample was handwritten by the participant on

the Quest requisition form. Study staff reconciled possible mismatched test results by reviewing

data for requisition numbers entered in the app, shipment tracking data, and contact reports. If

mismatched data could not be adequately aligned, those data were considered ineligible due to

failed quality-checks. Additional adjudication undertaken by the study team included a manual

review of all Ag-RDT images for participants who either had a self-reported positive, don't know,

or invalid Ag-RDT result or if they tested positive on molecular test at any point during the study.

All data were de-identified and shared with the FDA throughout the study. At the end of the

study, the final and cleaned dataset was shared with the FDA and company-specific data were

shared with the companies. All data will be made available on the NIH Data Hub once the main

findings from this study are published.

RESULTS

Enrollment: In total, 7,361 participants enrolled in the study between October 18, 2021 and

February 15, 2022 (Figure 1a). Due to complications with the company app, Test C enrollment

began on November 4, 2021, three weeks after Test A and B enrollment started (Figure 1b).

Following initial surges in recruitment, the enrollment waitlist was implemented on November

24, 2021 to allow for refinement of enrollment from geographic hotspots. In total, 492

participants tested positive on either molecular or Ag-RDT assays during the study, and 154

were eligible for analyses (Supplemental Figure 12).

Geographic and Sociodemographic Participant Characteristics: The geographic and

sociodemographic characteristics of study participants changed over the course of the study,

reflecting the shifts in the enrollment approach. In total, participants from 44 of the 48 mainland

U.S. states enrolled in the study (Figure 2). In October, the majority of initial study recruitment

occurred on a college campus in Wisconsin, resulting in a young, predominantly white, student

population (Figure 2; Table 1). Additionally, only 3.1% of enrolled participants in October were

unvaccinated for SARS-CoV-2. In November, study recruitment was expanded throughout the

United States, with enrollment from more than 20 different states. Participants from rural

populations comprised 14% of the participants recruited in November. In December and

January, study enrollment shifted to prioritize unvaccinated participants, preferentially pulling

these participants from the study waitlist, resulting in 24.6% and 21.4% of monthly enrollment

being unvaccinated (Table 1). In January, recruitment efforts also focused on increasing racial

and ethnic diversity in the study population, and the minority of participants enrolled during

January identified as White (42.6%). Additionally, 10.5% of participants enrolled in January were

of Hispanic origin.

Operational Support and Logistics: Throughout the study, there were 11,646 contacts between

coordinators and 4,389 distinct participants (Supplemental Table 2). This accounted for 33,356

minutes of coordination time. Coordinators and participants communicated by phone call

(39.7%), email (30.6%), voicemail (29.7%), and push notification within the study app (4.2%).

The most common reason for contact was to share COVID-19 test results from molecular tests,

which accounted for 24.3% of all calls. Other common reasons for contact included testing

reminders (19.1%), shipping and receipt of test kits (16.7%), compensation (16.3%), and

clarifying the testing schedule (10.4%). The company-generated app for Test C was initially only

compatible with certain smartphones; therefore, we delayed enrollment for Test C by two weeks

and troubleshooted the app with the company, to ensure participants were able to use the app

appropriately (Figure 1a). Further, the decentralized design necessitated an increased reliance

on shipping vendors, allowing us to reach participants across the mainland US states. However,

this also required a variety of tracking methods to keep track of the 58,888 kits shipped. This

study spanned the holiday season, which resulted in additional shipping delays; 1.2% (n =728)

of packages were affected by logistical or participant errors that led to an unviable or missing

RT-PCR test result.

DISCUSSION

Using an innovative digital, site-less study approach, we developed recruitment and

enrollment strategies to capture new onset COVID-19 infections most effectively throughout the

country, resulting in the detection of nearly three times as many new-onset COVID-19 cases as

originally specified. The digital site-less approach allowed us to seamlessly and dynamically

change enrollment patterns and sample different populations based on the evolving nature of

the pandemic, to assess rapid diagnostics with agility, efficiency, and rigor among asymptomatic

individuals.

The digital site-less approach offered great agility to alter the recruitment strategy to fit

our needs throughout the evolution of the study. Initially, to iron out the study logistics, we

opened study recruitment in October 2021 to members of a Midwestern university marching

band who were traveling together, where we anticipated a high amount of unmasked, close

contact interactions. This group enrollment is reflected in the demographics of participants in

October, who were younger and had a higher proportion of white participants than participants

recruited in November through January. Later, we were able to geographically alter the

sampling to enroll participants from throughout the United States and use a waitlist to selectively

sample certain populations by zip-code, determined by community prevalence of COVID-19,

and demographics to ensure we were curating a representative sample. For example, after

seeing low enrollment of participants over age 65 years in October through December, in

January, we selectively pulled those over 65 years of age off the waitlist, increasing the

proportion of participants in this group from 1.5% in October to 13.4% in January. Additionally,

the recruitment strategy resulted in 16.6% of all enrolled participants being unvaccinated,

matching nationwide estimates for those over 5 years of age (CDC data tracker). The waitlist

approach also allowed us to ensure that enrollment was not solely clustered among those who

have greatest access to recruitment strategies, but rather gave the time for information to

disseminate to and within various communities.

The remote design also resulted in gains in study efficiency, in terms of both coordinator

time and cost. Instead of requiring coordinators to schedule and supervise serial sample

collections for each participant, the virtual, site-less design allowed participants to test in their

homes and on their time, increasing accessibility to individuals with various employment and

school schedules, as well as living situations. According to the study coordination logs, direct

participant-coordinator phone calls averaged to just over 1-hour per day (82.3 minutes over 161

days of the study) and consisted primarily of testing reminders and returning molecular test

results to participants. As clinical research coordinators on average support upwards of seven

studies concurrently and approximately two-thirds of coordinators report being expected to work

more time on studies than allotted, it is important to optimize study coordination time, while

maintaining quality and consistency.[14] Here, we showed the ability for site-less digital trials to

run with minimal participant-coordinator interaction, while maintaining high enrollment and

adherence to the study protocol.

Site-less cohort studies have become increasingly common, as advances in technology

have made virtual recruitment and engagement more feasible.[15] However, digital products and

solutions in clinical research remain underutilized.[16] Site-less studies can not only facilitate

recruitment and participant engagement, but they can also enhance scientific rigor and design.

Through coordination with shipping services, home-test distributors, and clinical labs, we

organized shipments of study supplies to participants on enrollment, which allowed participants

to start testing at home within 24 to 48 hours of enrollment. Further, we coordinated the pick-up

and shipment of biological samples to the central laboratory, which has seldom been done

within the framework of a digital study. The success of these workflows opens the door for the

adaptation of site-less studies to answer many complex research questions, by integrating

survey responses, biological samples, and home health monitoring.

There are potential limitations to the study. We did not require participants to be under

video observation while performing the Ag-RDT or collecting samples for molecular tests.

However, our study facilitated use of these tests 'as intended' and 'as authorized' by the FDA

and therefore may represent better approximation of real-world performance of the tests than

traditional clinical studies. Additionally, the smartphone app required participants to take images

of the Ag-RDT; therefore, we could verify the Ag-RDT results for all participants. Due to the

scale and nature of this study, we used commercial vendors for assembly and distribution of the

testing kits, which precluded our ability to provide study-specific written instructions enclosed

within the kit; we instead relied on providing all study-specific instructions through the

smartphone app. This resulted in confusion for some participants who did not start testing

immediately after receiving the test kits or did not perform both Ag-RDT and PCR tests

concurrently. However, our study team was able to detect these instances and intervene

accordingly. Because of the logistical constraints, we could not facilitate a cold-chain

transportation of the collected specimen, which preclude our ability to perform viral culture

studies. Sample collection for molecular tests required participants to handwrite the date of

sample collection, and laboratory data had to be linked with Ag-RDT data based on Participant

ID and testing date, which resulted in mismatches and required substantial manual effort for

reconciling differences. Finally, the requirement of smartphone ownership to participate in the

study disadvantages people without smartphones. However, smartphone use is ubiquitous and

has been accelerated by the SARS-CoV-2 pandemic.[17] Additionally, we submit that the barrier

to participation created by requiring a smartphone is lesser than that created by requiring

participants to travel to a clinical study site, multiple times during the study.

These limitations notwithstanding, this study represents the most robust attempt at

understanding the performance of Ag-RDT for SARS-CoV-2 detection among asymptomatic

participants. We summarize the advantages of our digital siteless approach in Table 2 and

outline recommendations for future digital studies. The collaboration between the NIH, FDA, and

the RADx Clinical Studies Core allowed for development of a protocol that was innovative and a

study that will provide tremendous value to federal agencies, academic researchers and

companies for elucidating key questions related to raid antigen tests' performance. Future

collaborative efforts to develop best practice guidelines and infrastructure for performing digital

clinical studies are needed to advance scientific community's ability to perform rigorous clinical

research and answer vexing questions.

Data Availability: The datasets generated during the current study are available through the
RADx Datahub (https://www.radxdatahub.info/).

Acknowledgment: This study was funded by the NIH RADx Tech program under
3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this
manuscript are those of the authors and do not necessarily represent the views of the National
Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood
Institute; the National Institutes of Health, or the U.S. Department of Health and Human
Services. Salary support from the National Institutes of Health U54HL143541, R01HL141434,
R01HL137794, R61HL158541, R01HL137734, U01HL146382 (AS, DDM), U54EB007958-13
(YCM, MLR), AI272201400007C, UM1AI068613 (YCM). We are grateful to our study
participants and to our collaborators from the National Institute of Health (NIBIB and NHLBI)
who provided scientific input into the design of this study and interpretation of our results, but
could not formally join as co-authors due to institutional policies and to the Food and Drug
Administration (Office of In Vitro Diagnostics and Radiological Health) for their involvement in
the primary TUAH study. We received meaningful contributions from Drs. Bruce Tromberg, Jill
Heemskerk, Felicia Qashu, Dennis Buxton, Erin Iturriaga, Jue Chen, Andrew Weitz, and Krishna
Juluru. We are thankful to the developers of the rapid antigen tests, who donated their tests for
research use in this study. We are greatly appreciative of the contribution to this study by the
numerous staff at UMass Chan, including critical support from Karen Gilliam, Mary Janet
McCarthy, Amber Showers, Cynthia Kinahan, Kimberly Cantin, and Danielle Howard. We would
also like to acknowledge the support provided by clinical coordinators from Threewire, Inc. We
are thankful to county health departments across the country who helped with recruitment for
this siteless study by spreading the word in their networks.

Competing Interest Statement
VK is principal, and TS, SS, CN, ES, and EH are employees of the health care technology
company CareEvolution, which was contracted to configure the smartphone study app, provide
operational and logistical support, and collaborate on overall research approach. LS and LR are
employees of Quest Diagnostics LLC, which was contracted to provide direct-to-consumer kits,
logistical support for nationwide RT-PCR testing, and operational support for producing
molecular testing results. DDM reports consulting and research grants from Bristol-Myers
Squibb and Pfizer, consulting and research support from Fitbit, consulting, and research support
from Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial
research support from Apple Computer, consulting/other support from Heart Rhythm Society.
YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-
related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives
funding support to Johns Hopkins University from miDiagnostics. AS receives non-financial
support from CareEvolution for collaborative research activities. Additional authors declare no
financial or non-financial competing interests.

References:

1. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) | FDA. Accessed July 4, 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised

2. Kanji JN, Zelyas N, MacDonald C, et al. False negative rate of COVID-19 PCR testing: a discordant testing analysis. *Virology Journal*. 2021;18(1):13. doi:10.1186/s12985-021-01489-0

3. Wei Z, Ryhana M, Elizabeth S, J BG, J MA. Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens. *Journal of Clinical Microbiology*. 2022;58(8):e00743-20. doi:10.1128/JCM.00743-20

4. Lowe CF, Matic N, Ritchie G, et al. Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays. *Journal of Clinical Virology*. 2020;128:104387. doi:https://doi.org/10.1016/j.jcv.2020.104387

5. Smith RL, Gibson LL, Martinez PP, et al. Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 Infection. *The Journal of Infectious Diseases*. 2021;224(6):976-982. doi:10.1093/infdis/jiab337

6. CDC COVID Data Tracker. Accessed May 12, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions

7. Herbert C, Kheterpal V, Suvarna T, et al. Design and Preliminary Findings of Adherence to the Self-Testing for Our Protection From COVID-19 (STOP COVID-19) Risk-Based Testing Protocol: Prospective Digital Study. *JMIR Form Res*. 2022;6(6):e38113. doi:10.2196/38113

8. Lamberti MJ, Getz K. Profiles of New Approaches to Improving the Efficiency and Performance of Pharmaceutical Drug Development. *Tufts White Paper*. Published online 2015.

9. Hirsch IB, Martinez J, Dorsey ER, et al. Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action. *Clinical Therapeutics*. 2017;39(5). doi:10.1016/j.clinthera.2017.03.018

10. Gray DM, Nolan TS, Gregory J, Joseph JJ. Diversity in clinical trials: an opportunity and imperative for community engagement. *The Lancet Gastroenterology and Hepatology*. 2021;6(8). doi:10.1016/S2468-1253(21)00228-4

11. Clark LT, Watkins L, Piña IL, et al. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. *Current Problems in Cardiology*. 2019;44(5). doi:10.1016/j.cpcardiol.2018.11.002

12. National Academies of Sciences Engineering and Medicine. *Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups*. The National Academies Press; 2022. doi:https://doi.org/10.17226/26479.

13. Inan OT, Tenaerts P, Prindiville SA, et al. Digitizing clinical trials. *npj Digital Medicine*. 2020;3(1):101. doi:10.1038/s41746-020-0302-y

14. Speicher LA, Fromell G, Avery S, et al. The critical need for academic health centers to assess the training, support, and career development requirements of clinical research coordinators:

recommendations from the Clinical and Translational Science Award Research Coordinator
Taskforce. *Clin Transl Sci*. 2012;5(6):470-475. doi:10.1111/j.1752-8062.2012.00423.x

15.   Banks MA. Core Concept: In the wake of COVID-19, decentralized clinical trials move to center
stage. *Proc Natl Acad Sci U S A*. 2021;118(47):e2119097118. doi:10.1073/pnas.2119097118

16.   Marra C, Gordon WJ, Stern AD. Use of connected digital products in clinical research following
the COVID-19 pandemic: a comprehensive analysis of clinical trials. *BMJ Open*.
2021;11(6):e047341. doi:10.1136/bmjopen-2020-047341

17.   Demographics of Mobile Device Ownership and Adoption in the United States | Pew Research
Center. Accessed July 31, 2022. https://www.pewresearch.org/internet/fact-sheet/mobile/

     Tables and Figures:

     Table 1: Test Us at Home Participant Demographics by Month of Enrollment

	October N=415	November N=3701	December N=1592	January N=1653	Total N=7361
Test Assigned: n (%)					
Test A	80 (19.3)	1,474 (39.8)	375 (23.6)	530 (32.1)	2,459 (33.4)
Test B	335 (80.7)	1,231 (33.3)	375 (23.6)	565 (34.2)	2,506 (34.0)
Test C	0 (0.0)	996 (26.9)	842 (52.9)	558 (33.8)	2,396 (32.6)
Vaccination Doses: n (%)					
1	51 (12.3)	1,176 (31.8)	418 (26.3)	32 (1.9)	1,677 (22.8)
2	350 (84.3)	2,062 (55.7)	513 (32.2)	352 (21.3)	3,277 (44.5)
3+	0 (0.0)	0 (0.0)	269 (16.9)	915 (55.4)	1,184 (16.1)
Unvaccinated	13 (3.1)	462 (12.5)	392 (24.6)	354 (21.4)	1,221 (16.6)
Don't know	1 (0.2)	1 (0.1)	0 (0.0)	0 (0.0)	2 (0.1)
Age Category: n (%)					
Less than 18 years	0 (0.0)	417 (11.3)	199 (12.5)	164 (9.9)	780 (10.6)
18-45 years	384 (92.5)	2,156 (58.3)	851 (53.5)	878 (53.1)	4,269 (58.0)
45-65 years	25 (6.0)	871 (23.5)	392 (24.6)	390 (23.6)	1,678 (22.8)
Over 65 years	6 (1.5)	257 (6.9)	150 (9.4)	221 (13.4)	634 (8.6)
Gender: n (%)					
Female	232 (55.9)	2,340 (63.2)	1,045 (65.6)	1,025 (62.1)	4,642 (63.1)
Male	131 (31.6)	1,208 (32.6)	458 (28.8)	523 (31.7)	2,320 (31.5)
Nonbinary	28 (6.8)	49 (1.3)	20 (1.3)	19 (1.2)	116 (1.6)
Transgender	14 (3.4)	20 (0.5)	11 (0.7)	2 (0.1)	47 (0.6)
No answer	10 (2.4)	84 (2.3)	58 (3.6)	84 (5.1)	236 (3.2)
Race/Ethnicity: n (%)					
White	358 (86.3)	3,167 (85.6)	1,249 (78.4)	703 (42.6)	5,477 (74.4)
African American/Black	15 (3.6)	95 (2.6)	94 (5.9)	159 (9.6)	363 (4.9)
Asian	5 (1.2)	98 (2.7)	50 (3.1)	302 (18.3)	455 (6.2)
Pacific Islander	0 (0.0)	1 (0.1)	1 (0.1)	25 (1.5)	27 (0.4)
Native American/Alaskan Native	3 (0.7)	19 (0.5)	9 (0.6)	10 (0.6)	41 (0.6)

Other	9 (2.2)	83 (2.2)	49 (3.1)	192 (11.6)	333 (4.5)
Multiracial	13 (3.1)	137 (3.7)	66 (4.1)	129 (7.8)	345 (4.7)
No answer	12 (2.9)	101 (2.7)	74 (4.7)	133 (8.1)	320 (4.4)
Hispanic: n (%)	24 (5.8)	243 (6.6)	88 (5.5)	174 (10.5)	529 (7.2)
Geographic Setting					
Rural	25 (6.0)	521 (14.1)	188 (11.8)	137 (8.3)	871 (11.8)
Suburban	238 (57.4)	1,997 (54.0)	900 (56.5)	797 (48.2)	3,932 (53.4)
Urban	144 (34.7)	1,126 (30.4)	456 (28.6)	643 (38.9)	2,369 (32.2)
No answer	8 (1.9)	57 (1.5)	48 (3.0)	76 (4.6)	189 (2.6)
Highest Level of Education: n (%)					
Did not finish high school	0 (0.0)	331 (8.9)	160 (10.1)	131 (7.9)	622 (8.5)
High school graduate	173 (41.7)	328 (8.9)	145 (9.1)	179 (10.8)	825 (11.2)
Some college	155 (37.4)	830 (22.4)	336 (21.1)	378 (22.9)	1,699 (23.1)
Bachelor's Degree or higher	78 (18.8)	2,027 (54.8)	833 (52.3)	830 (50.2)	3,768 (51.2)
Don't know	1 (0.2)	45 (1.2)	18 (1.1)	19 (1.2)	83 (1.1)
No answer	8 (1.9)	140 (3.8)	100 (6.3)	116 (7.0)	364 (4.9)
Employment Status: n (%)					
Unemployed	22 (5.3)	414 (11.2)	134 (8.4)	169 (10.2)	739 (10.0)
Retired	8 (1.9)	253 (6.8)	121 (7.6)	170 (10.3)	552 (7.5)
Student	265 (63.9)	656 (17.7)	273 (17.2)	239 (14.5)	1,433 (19.5)
Working now	106 (25.5)	2,230 (60.3)	967 (60.7)	934 (56.5)	4,237 (57.6)
Other	3 (0.7)	55 (1.5)	27 (1.7)	30 (1.8)	115 (1.6)
No answer	11 (2.7)	93 (2.5)	70 (4.4)	111 (6.7)	285 (3.9)

Table 2. Summary of features of this study and opportunity for improvement

Challenges	Innovation	Opportunity for improvement
Widespread outreach to asymptomatic individuals	Democratized participation such that anyone, anywhere, anytime can choose to participate through a smartphone without needing to travel to a clinical study site or recruitment centers	Requirement of smartphone to enroll can prevent some people from participating. Approaches that loan study smartphones or leverage community-health workers as digital studies' liaisons can help overcome this limitation
Engagement of diverse communities	A dedicated team met with county health workers and community stakeholders from across the country to promote awareness of the study and participation among people of color, indigenous heritage, and rural locations	A network of community partners and stakeholders for digital clinical studies that inform, plan, and conduct outreach efforts can help further enhance participation of historically underrepresented populations
Recruitment from SARS-CoV-2 "hotspot"	Use of CDC daily case reports and projects to identify geographical regions where community outreach efforts were enhanced and which were identified as 'preferred regions for enrollment'	Promoting peer-to-peer recruitment from hotspots through the use of the smartphone apps
Refinement of enrollment	Adding a layer of prioritization to allow cohort composition such that participants from "hotspots" and those that improve diverse representation of the enrolled cohort	Automatically adaptive priority criteria that does not require manual input or decision-making but can allow manual override
Consenting participants including children > 2 years old	Self-contained description of consent, including brief description of key parts of the study displayed through the smartphone app	Use of participatory videos that explain the study objectives and activities embedded within the smartphone app
Assigning rapid antigen tests	Pre-specified criteria that assigned tests to participants automatically	Adaptive algorithm that refines criteria to create balanced cohorts based on multiple variables
Distributing testing kits	Asynchronous assembly and shipment of kits from commercial vendors	Synchronous assembly and shipment of kits such that all materials arrive in box instead of different boxes
Collecting samples for molecular tests	Direct-to-consumer kits for nasal swabs that were returned using FedEx overnight prepaid envelopes	Courier pickup options that can be invoked from within the study app

Performing up to three separate molecular assays in CLIA laboratories	Automated ordering of two tests and manual ordering of additional tests when discordance was observed	Automated ordering of discordant testing with streamlined data collection
Serial testing within a specific window (44-52 hours apart)	Automated app notification and text messages every two hours during the testing window	Providing the option of defining notification frequency during the testing window to the participants
Verification of rapid antigen testing results	In-app widget to allow participants to take an image of rapid antigen tests that were later verified by the coordinators	Automated readers that verify that an image of rapid antigen test was collected and that the test result matches the result manually entered by the participant
Data collection and quality	Data fidelity and timestamp for each element collected within the study app and collation of disparate datafeed from the molecular testing laboratory	Minimizing user entry of free-text or handwritten data
Participant reimbursement	Batch processing of prepaid Bank of America cards that are mailed to participants' home	Automated delivery of reimbursement through smartphone app once the requirements are met

Figure 1: Test Us At Home Study Enrollment

Figure 1a:

Test Us At Home Enrollment: October 18, 2021-January 22, 2022

Figure 1b:

Test Us At Home Enrollment by Test

a: Test A and B enrollment opens to individuals with specific group codes on October 18, 2021; b: Enrollment opens nationwide on October 26, 2021; c: Test C enrollment starts on November 4, 2021; d: Enrollment waitlist approach implemented on November 24, 2021

Figure 2: Test Us at Home Enrollment by State and Month, October 2021-January 2022

Note: COVID-19 monthly incidence calculated from CDC COVID Data Tracker[6]

Figure 3: CONSORT diagram of the Test Us At Home Study

CONSORT diagram for data included in the final dataset shared with the FDA (all data)

7,361 participants enrolled in the study between Oct 18, 2021 and Jan 31, 2022

58 participants reported infection in previous 3 months
549 Did not do a single OTC or PCR test
43 participants did not do any OTC tests
221 participants did not do any RT-PCR tests

6,490 participants completed testing

5,998 participants tested negative on both tests

492 participants had at-least one positive test on OTC or RT-PCR test

9 participants switched rapid antigen tests during the study[a]
5 participants failed quality-check[b]
143 symptomatic on first day of testing
79 positive on first RT-PCR test (composite method)

256 participants were asymptomatic and tested negative on PCR comparator[c] to start the study

88 participants tested negative on PCR
6 participants missing comparator results from study day 1
6 participants had no OTC results within 48 hours of index PCR positive

154 eligible for primary analysis

41 Company A   58 Company B   55 Company C

a= participants replaced their assigned rapid antigen tests with commercially obtained rapid antigen tests; b= dates of RT-PCR testing could not be verified based on triangulation of self-reported, shipping, and resulting data; A, B, and C refer to rapid antigen test assignment. c = at-least two positive molecular assays from a single sample per participant (Roche Cobas 6800, Quest LDT, Hologic Aptima)